PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis ; day:24 ; month:9 ; year:2020 ; pages:1-11
European journal of nuclear medicine and molecular imaging ; (24.9.2020), 1-11
- Urheber
-
Seifert, Robert
Kessel, Katharina
Schlack, Katrin
Weber, Manuel
Herrmann, Ken
Spanke, Maximilian
Fendler, Wolfgang P.
Hadaschik, Boris
Kleesiek, Jens
Schäfers, Michael
Weckesser, Matthias
Boegemann, Martin
Rahbar, Kambiz
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-020-05040-1
- URN
-
urn:nbn:de:101:1-2020111218001764602998
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Seifert, Robert
- Kessel, Katharina
- Schlack, Katrin
- Weber, Manuel
- Herrmann, Ken
- Spanke, Maximilian
- Fendler, Wolfgang P.
- Hadaschik, Boris
- Kleesiek, Jens
- Schäfers, Michael
- Weckesser, Matthias
- Boegemann, Martin
- Rahbar, Kambiz
- SpringerLink (Online service)
Ähnliche Objekte (12)
![2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke](/assets/placeholder/searchResultMediaUnknown.png)
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy
Ressourceneffizienz durch Produktionsplanung und Lean Production
Neuartiges Antriebskonzept zum Fahren, Lenken und Heben
The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?
Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy
Ressourceneffizienz durch Produktionsplanung und Lean Production
Neuartiges Antriebskonzept zum Fahren, Lenken und Heben
The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?
Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy
Ressourceneffizienz durch Produktionsplanung und Lean Production
Neuartiges Antriebskonzept zum Fahren, Lenken und Heben
The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?